On Friday, Developers of Russia’s Sputnik V coronavirus vaccine announced that India-based drugmaker Hetero will produce over 100 million doses of the vaccine.
In a statement the Russian Direct Investment Fund (RDIF) said: “Hetero, one of India’s leading generic pharmaceutical companies, have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection — Sputnik V,” adding that production was expected to start in early 2021.
Russia also announced that the Sputnik V vaccine will be priced at $10 per dose on international markets, costing less than some other registered Covid-19 vaccines.
Currently, the third and final phase of trials is underway, with some 40,000 volunteers involved in blind testing of the vaccine that uses two different human adenovirus vectors.
